HealthDay - THURSDAY, April 28 (HealthDay News) -- Boceprevir, a new medication from Merck & Co. that changes the way hepatitis C is treated, won unanimous support Wednesday from a panel of experts convened by the U.S. Food and Drug Administration.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.